{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "currency": "EUR", "market": "dr_market", "esgPopulated": false, "gmtOffSetMilliseconds": 7200000, "exchange": "FRA", "longName": "Fate Therapeutics, Inc.", "shortName": "FATE THERAPEUTICS DL-,001", "regularMarketPrice": 4.796, "regularMarketChangePercent": 0.08347636, "messageBoardId": "finmb_39268712", "marketState": "REGULAR", "fiftyTwoWeekHighChangePercent": -0.8640204, "fiftyTwoWeekLow": 3.8555, "fiftyTwoWeekHigh": 35.27, "earningsTimestamp": 1683147600, "earningsTimestampStart": 1690887540, "earningsTimestampEnd": 1691409600, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "fiftyTwoWeekLowChange": 0.9405, "fiftyTwoWeekLowChangePercent": 0.24393724, "fiftyTwoWeekRange": "3.8555 - 35.27", "fiftyTwoWeekHighChange": -30.474, "epsTrailingTwelveMonths": -2.19, "epsForward": -2.65, "epsCurrentYear": -2.25, "priceEpsCurrentYear": -2.1315556, "sharesOutstanding": 98384496, "bookValue": 4.863, "fiftyDayAverage": 5.26243, "fiftyDayAverageChange": -0.4664302, "fiftyDayAverageChangePercent": -0.08863399, "twoHundredDayAverage": 14.96463, "twoHundredDayAverageChange": -10.168631, "twoHundredDayAverageChangePercent": -0.679511, "marketCap": 477873888, "forwardPE": -1.8098112, "priceToBook": 0.9862225, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.9 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1380780000000, "priceHint": 4, "regularMarketChange": 0.004000187, "regularMarketTime": 1683872225, "regularMarketDayHigh": 4.796, "regularMarketDayRange": "4.796 - 4.796", "regularMarketDayLow": 4.796, "regularMarketVolume": 500, "regularMarketPreviousClose": 4.792, "bid": 4.656, "ask": 4.698, "bidSize": 1400, "askSize": 1300, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 4.796, "averageDailyVolume3Month": 41, "averageDailyVolume10Day": 0, "symbol": "F6T.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "12278 Scripps Summit Drive", "city": "San Diego", "state": "CA", "zip": "92131", "country": "United States", "phone": "858 875 1800", "website": "https://www.fatetherapeutics.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.", "fullTimeEmployees": 551, "companyOfficers": [{"maxAge": 1, "name": "Mr. J. Scott Wolchko", "age": 52, "title": "Founder, CEO, Pres & Director", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 645000, "fmt": "645k", "longFmt": "645,000"}, "exercisedValue": {"raw": 3854968, "fmt": "3.85M", "longFmt": "3,854,968"}, "unexercisedValue": {"raw": 1599920, "fmt": "1.6M", "longFmt": "1,599,920"}}, {"maxAge": 1, "name": "Mr. Edward J. Dulac III", "age": 46, "title": "Chief Financial Officer", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": {"raw": 455000, "fmt": "455k", "longFmt": "455,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Cindy R. Tahl", "age": 49, "title": "Gen. Counsel & Corp. Sec.", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": {"raw": 455000, "fmt": "455k", "longFmt": "455,000"}, "exercisedValue": {"raw": 3890153, "fmt": "3.89M", "longFmt": "3,890,153"}, "unexercisedValue": {"raw": 656415, "fmt": "656.41k", "longFmt": "656,415"}}, {"maxAge": 1, "name": "Dr. Bahram  Valamehr Ph.D.", "age": 45, "title": "Chief R&D Officer", "yearBorn": 1977, "fiscalYear": 2022, "totalPay": {"raw": 455000, "fmt": "455k", "longFmt": "455,000"}, "exercisedValue": {"raw": 1390425, "fmt": "1.39M", "longFmt": "1,390,425"}, "unexercisedValue": {"raw": 939510, "fmt": "939.51k", "longFmt": "939,510"}}, {"maxAge": 1, "name": "Dr. Yu-Waye  Chu M.D.", "age": 54, "title": "Chief Medical Officer", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 455000, "fmt": "455k", "longFmt": "455,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jim  Beitel M.B.A.", "title": "Sr. VP of Corp. Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Sarah  Cooley", "title": "Sr. VP of Clinical Translation", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jerome  Bressi Ph.D.", "title": "Sr. VP of Regulatory & Quality", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Brian T. Powl M.B.A., M.S.", "age": 48, "title": "Chief Commercial Officer", "yearBorn": 1974, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}